<DOC>
	<DOCNO>NCT02595255</DOCNO>
	<brief_summary>While child spontaneously recover menstruation experience normal puberty chemotherapy , ovarian reserve may impair treatment induce future infertility . Fertility preservation currently propose select prepubertal patient high risk premature ovarian failure treatment ( mostly condition regimen bone marrow transplantation ) . For patient low moderate risk , counsel difficult fertility preservation procedure usually propose patient marker ovarian reserve validate young population ass individual risk . The primary objective study prevent long-term treatment-related infertility detect young patient normally progress menarche reduce ovarian reserve . These patient may benefit particular follow-up fertility preservation procedure .</brief_summary>
	<brief_title>AMH Predictor Infertility Risk Children With Cancer ( CHANCE )</brief_title>
	<detailed_description>In clinical trial , prospectively evaluate AMH level treatment ( 18 year old ) large cohort pre- post-pubertal child treat cancer . The child enrol young patient 3 14 year old newly diagnose cancer benign disease treat chemotherapy and/or pelvic irradiation . They belong one 3 group ( modify Wallace et al , 2005 ) : - High risk - Moderate/Low risk - No risk ( control group ) Primary endpoint : Evaluate AMH potential biomarker ovarian reserve prepubertal/pubertal girl treat chemotherapy ( classified accord AAD score ) Secondary endpoint : - Evaluate association post-treatment ovarian reserve AMH pretreatment value patient consider moderate low risk . - Identify new patient group may benefit fertility preservation - Compare gonadotoxicity chemotherapy regimen accord pubertal status . - Study relation AMH level pubertal age , menstruation cycle regularity , hormonal level ( FSH , Å“stradiol , testosterone ) bone age . Different parameter assess inclusion , end treatment follow-up ( every year first 3 year every 2 year end study ) Oncological outcome The patient follow progression survival per standard local practice . Ovarian reserve function : Ovarian reserve evaluate base hormonal dosage different time study : FSH , AMH , estradiol , testosterone LH . Menstrual function evaluate collect information pubertal status ( spontaneous induce puberty ) menstrual cycle characteristic Puberty evaluation : All child evaluation TANNER pubertal stage 9 year age ( later &gt; 9 year old time inclusion ) year end puberty ( patient reach Tanner stage 5 ) . An X-ray left hand wrist carry bone age evaluation 9-11 13 year old .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Patients 3 14 year old include Belong one 3 group ( modify Wallace et al , 2005 ) : High risk : Conditioning therapy bone marrow transplantation pelvic irradiation Moderate/Low risk : Pathologies treat chemotherapy regimen moderate low risk induce ovarian function insufficiency : AML , osteosarcoma , Ewing sarcoma , neuroblastoma , nonHodgkin lymphoma , Hodgkin lymphoma , soft tissue sarcoma , ALL , Wilms tumour , retinoblastoma . No risk ( control group ) : patient chronic benign disease malignancies n't receive chemotherapy gonadotoxic treatment . CNS irradiation , cerebral tumour Current previous ovarian disease/surgery Familial history premature ovarian failure ( iatrogenic surgical origin ) Previous know severe chronic disease potentially affect normal growth puberty ( diseases induce malnutrition , anorexia , genetic/congenital disorder Turner , Kallman , BPES syndromes , uncontrolled severe diabetes , Cushing Syndrome , autoimmune disease , cystic fibrosis , severe renal dysfunction ) Genetic/congenital disorder induce mental retardation</criteria>
	<gender>Female</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>chemotherapy/GnRH analogues/lymphoma/children/fertility</keyword>
</DOC>